---
document_datetime: 2023-09-21 22:03:23
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.4875587
conversion_datetime: 2025-12-28 01:23:31.238634
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tenofovir disoproxil Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0027              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 06/06/2023                          |                                             | SmPC and PL                      |           |
| N/0026               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 22/02/2023                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0025/G   | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 29/08/2022   |            | SmPC, Annex II and PL   | C.I.2.a - To update section 5.1 of the SmPC in alignment with the reference product.                                                                                                                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0024      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                            | 06/05/2022   |            | PL                      |                                                                                                                                                                                                                                                                                          |
| T/0023      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/09/2021   | 19/10/2021 | SmPC, Labelling and PL  |                                                                                                                                                                                                                                                                                          |
| R/0022      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/06/2021   | 26/08/2021 | SmPC and PL             | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Tenofovir disoproxil Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0021/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                                                                                                                                                                                                        | 22/03/2021   | n/a        |                         |                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|             | specification limits A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   |            |            |                                  |                                                          |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------|
| IA/0020/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                           | 03/02/2021 | n/a        |                                  |                                                          |
| IB/0019     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                            | 28/01/2021 | 26/08/2021 | SmPC, Annex II, Labelling and PL |                                                          |
| PSUSA/2892/ | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/11/2020 | 11/01/2021 | SmPC, Annex                      | Refer to Scientific conclusions and grounds recommending |

<div style=\"page-break-after: always\"></div>

| 202003             | tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            | II, Labelling and PL   | the variation to terms of the Marketing Authorisation(s) ' for PSUSA/2892/202003.                                                          |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0017/G        | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 27/03/2020 | 11/01/2021 | Annex II and PL        |                                                                                                                                            |
| PSUSA/2892/ 201903 | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                        | 14/11/2019 | 13/01/2020 | SmPC                   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for PSUSA/2892/201903. |
| IB/0016            | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                                                                                                                                                                                                                                                                                                                                  | 16/08/2019 | 24/10/2019 | SmPC, Labelling and PL |                                                                                                                                            |
| IB/0014            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                              | 21/06/2019 | 24/10/2019 | SmPC and PL            |                                                                                                                                            |
| IB/0013/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/05/2019 | 24/10/2019 | Annex II               |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                    |            |            |                        |           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| IB/0012 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                               | 05/03/2019 | 24/10/2019 | SmPC and PL            |           |
| IA/0011 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                        | 14/01/2019 | n/a        |                        |           |
|         | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished | 17/12/2018 | 24/10/2019 | SmPC, Labelling and PL | IB/0010/G |

<div style=\"page-break-after: always\"></div>

|                    | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/2892/ 201803 | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/10/2018 | n/a        |             | PRAC Recommendation - maintenance |
| IAIN/0009          | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24/10/2018 | 24/10/2019 | SmPC        |                                   |
| IB/0007/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 27/11/2017 | 19/02/2018 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/2892/ 201703   | Periodic Safety Update EU Single assessment - tenofovir disoproxil                                                                                                                                                                                           | 26/10/2017   | n/a        |                        | PRAC Recommendation - maintenance   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IAIN/0006            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                           | 10/08/2017   | n/a        |                        |                                     |
| IB/0003              | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                          | 19/07/2017   | 19/02/2018 | SmPC, Labelling and PL |                                     |
| IA/0002              | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                   | 11/05/2017   | n/a        |                        |                                     |
| IB/0001              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 13/03/2017   | 19/02/2018 | SmPC and PL            |                                     |